囊性与实性胰腺神经内分泌肿瘤的临床病理特征及长期结局:1727例多中心经验
该多中心回顾性研究纳入2000至2019年4个高容量中心接受胰腺切除术的1727例胰腺神经内分泌肿瘤(PanNET)患者,其中囊性177例(10.3%)、实性1550例(89.7%)。排除功能性和相关混杂因素后比较145例囊性与1059例实性PanNET,囊性者淋巴结转移(5.5% vs 24.0%,P<0.001)和远处复发(4.1% vs 14.4%,P<0.001)显著更少,长期生存更优。结论提示≤3 cm经EUS-FNA证实的囊性PanNET可考虑保守管理,>3 cm者宜行保留实质和淋巴结的切除。
要点
- 囊性PanNET淋巴结转移和远处复发率显著低于实性PanNET。
- ≤3 cm囊性PanNET淋巴结转移3.9%、复发3.1%,可考虑保守管理。
- >3 cm囊性PanNET建议行保留实质和淋巴结的切除术。
核心结论
- 囊性PanNET的生物学行为较实性PanNET更偏良性,长期生存更优。
研究设计与样本
- 多中心回顾性队列研究,纳入2000至2019年4个高容量中心接受胰腺切除术的1727例PanNET患者,中位年龄58.1岁(IQR 18.4),男性占53.3%。
主要发现
- 囊性PanNET占10.3%(177/1727),实性占89.7%(1550/1727)。
- 排除功能性和相关混杂因素后比较145例囊性与1059例实性PanNET,中位随访64个月,囊性者淋巴结转移5.5% vs 24.0%(P<0.001),远处复发4.1% vs 14.4%(P<0.001)。
- 肿瘤≤3 cm时,囊性PanNET淋巴结转移3.9% vs 17.8%(P<0.001),复发3.1% vs 8.4%(P=0.041)。
- 囊性PanNET无论肿瘤大小均具有更有利的长期生存。
关键数值与推荐
- 对于≤3 cm且经超声内镜引导细针穿刺(EUS-FNA)证实的囊性PanNET,可考虑保守管理。
- 对于>3 cm的囊性PanNET,宜行保留胰腺实质和淋巴结的切除术。
- 基线体能状态差的患者可不行囊性PanNET切除,而不影响总生存。
临床怎么用
- 临床遇到囊性PanNET时应与实性PanNET区别对待,评估其偏惰性的生物学行为。
- 对≤3 cm且EUS-FNA证实的囊性PanNET,可在充分评估后选择保守管理而非立即手术。
- 对>3 cm的囊性PanNET,手术应优先考虑保留实质和淋巴结的术式。
- 对基线体能状态差的患者,可权衡手术风险与获益,考虑不切除囊性PanNET。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the clinicopathologic features and long-term outcomes of cystic and solid pancreatic neuroendocrine tumors (PanNETs). BACKGROUND: PanNETs uncommonly present as cystic lesions. Whether cystic PanNETs represent a distinct clinical entity compared with solid PanNETs is controversial. METHODS: Clinicopathologic data of patients with resected PanNETs were collected from 4 high-volume centers between 2000 and 2019. Clinicopathologic characteristics and outcomes of patients with cystic and solid PanNETs were compared based on a 3 cm tumor size cutoff using the χ 2 test and Mann-Whitney U test. Survival estimates were calculated with the Kaplan-Meier method and log-rank test and multivariable analysis using a Cox proportional hazard model. RESULTS: Of the 1727 patients undergoing pancreatectomy for PanNET, the median age was 58.1 years (IQR: 18.4), and 53.3% were males. Of these, 177 (10.3%) were cystic, and 1550 (89.7%) were solid. Cystic PanNETs were more prevalent in patients with hereditary syndromes, less frequently functional, and more often located in the body/tail of the pancreas. After the exclusion of patients with functional tumors, World Health Organization G3 tumors, hereditary syndromes, neoadjuvant treatment, and metastatic stage, 145 cystic PanNETs were compared with 1059 solid PanNETs, and the median follow-up period of the cohort was 64 months. Cystic PanNETs demonstrated significantly fewer high-risk histopathologic features, lymph node (LN) metastases (5.5% vs 24.0%, P < 0.001), and distant recurrence (4.1% vs 14.4%; P < 0.001). Among tumors, ≤3 cm, cystic PanNETs had a low rate of LN metastases (3.9% vs 17.8%; P < 0.001), recurrence (3.1% vs 8.4%; P = 0.041), and low propensity to recur distantly. Cystic PanNETs had favorable long-term survival regardless of tumor size. CONCLUSIONS: Cystic PanNETs have a more benign course than their solid counterparts, and conservative management can be considered for endoscopic ultrasound-guided fine needle aspiration-proven cystic PanNETs ≤3 cm. Parenchyma and LN-sparing resections are warranted in patients with cystic PanNETs >3 cm. Patients with poor baseline performance status may forego cystic PanNET resection and not affect their overall survival.
引用
- Ventin M, Arya S, Cattaneo G, et al. Clinicopathologic Characteristics and Long-term Outcomes of Cystic Versus Solid Pancreatic Neuroendocrine Tumors: A Multi-institutional Experience With 1727 Patients. Ann Surg. 2025. PMID: 39781747. doi:10.1097/SLA.0000000000006624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。